Love him or hate him (and many people do both), Dr. Richard Pazdur -- director of the FDA's Office of Hematology and Oncology Products-- is the world's most important cancer drug regulator.
In an exclusive web interview, Dr. Pazdur tells BioCentury why the agency is racing to approve new cancer drugs. He says new targeted drugs and immunotherapies with unprecedented efficacy are the payoff from 20 years of basic science. He calls for greater patient engagement in drug development, says compassionate access should be improved, and predicts rapid uptake of biosimilars.
The four-part interview contains the segments:
· Cancer "Rocket Docket" – How the FDA is racing to approve new drugs because it is seeing unprecedented efficacy.
· Patient Power. Why the patient voice is critical to improving cancer drugs.
· Precision Medicine. How the agency is trying to make precision medicine a reality for cancer patients.
· Compelling Case. The case for doing more to create better cancer drugs for kids.
The complete video interview can be found here.
